Phar­ma­ceu­ti­cals: Crit­i­cal Anal­y­sis and Chal­lenges for Fu­ture

Uzbekistan Today (English) - - FRONT PAGE -

Un­der the chair­man­ship of the Pres­i­dent of Uzbek­istan, a meet­ing was held on Fe­bru­ary 6 de­voted to the anal­y­sis of the on­go­ing work on the de­vel­op­ment of the phar­ma­ceu­ti­cal in­dus­try and the def­i­ni­tion of ur­gent tasks for the fu­ture.

In Uzbek­istan, con­stant at­ten­tion is paid to im­prov­ing the health of the peo­ple, pro­vid­ing the pop­u­la­tion with qual­ity and af­ford­able medicines. In the past year, sev­eral meet­ings have been held on these is­sues. Ap­prox­i­mately 30 de­crees and de­crees aimed at ex­pand­ing the scale and im­prov­ing the qual­ity of med­i­cal care have been adopted.

Work has been car­ried out to im­prove the pro­vi­sion of the pop­u­la­tion and pub­lic health in­sti­tu­tions with af­ford­able medicines and med­i­cal prod­ucts. In par­tic­u­lar, in ac­cor­dance with the Pres­i­dent's De­cree, in Novem­ber 2017, the Agency for the De­vel­op­ment of the Phar­ma­ceu­ti­cal In­dus­try was es­tab­lished un­der the Min­istry of Health.

The sys­tem work car­ried out in the sphere gives its re­sults. Last year, 1.6 bil­lion con­di­tional pack­ages of medicines and med­i­cal prod­ucts were pro­duced, which is 34% more than in 2016.

Last year, 71 in­vest­ment projects were launched in the in­dus­try, 33 ob­jects were put into op­er­a­tion for $ 148 mil­lion, 76 new prod­ucts were pro­duced.

The meet­ing crit­i­cally an­a­lyzed the work car­ried out in the in­dus­try and noted the un­sat­is­fac­tory level of im­ple­men­ta­tion of the tasks set.

Most phar­ma­ceu­ti­cal com­pa­nies do not use mod­ern tech­nolo­gies, do not pay due at­ten­tion to the pro­duc­tion of medic­i­nal sub­stances, said Shavkat Mirziy­oyev. In­stead of switch­ing to a full pro­duc­tion cy­cle, en­ter­prises are still en­gaged in im­por­ta­tion from abroad and pack­ag­ing of fin­ished prod­ucts.

It was noted that only 12 out of 94 en­ter­prises have an in­ter­na­tional GMP cer­tifi­cate (Good Man­u­fac­tur­ing Prac­tice), which en­sures the recog­ni­tion of prod­ucts in other coun­tries. To ex­pand it, the lead­er­ship of the in­dus­try lacks ini­tia­tive. So, deep pro­cess­ing of licorice root for many years re­mained with­out due at­ten­tion. Only af­ter the in­struc­tion of the head of our state dur­ing the trip to Karakalpak­stan at the end of last year was es­tab­lished the As­so­ci­a­tion of or­ga­ni­za­tions for the pro­duc­tion and pro­cess­ing of licorice.

The need for spe­cial con­trol on this is­sue, the im­por­tance of the tran­si­tion from a sim­ple col­lec­tion of wild licorice root to the or­ga­ni­za­tion of plan­ta­tions and the deep pro­cess­ing of this raw ma­te­rial with the pro­duc­tion of medic­i­nal sub­stances and agents from it were em­pha­sized.

Crit­i­cized was the fact that most of the in­dus­try is lim­ited to the pro­duc­tion of drugs of a sim­ple for­mula. The phys­i­cal vol­ume of pro­duc­tion in the in­dus­try in 2017 grew by 34%, while the growth in value terms was only 16%.

De­spite the fact that do­mes­tic en­ter­prises have been granted var­i­ous priv­i­leges for the pro­duc­tion of im­port-sub­sti­tut­ing prod­ucts for a num­ber of years, cur­rently 74% of do­mes­tic de­mand is cov­ered by im­ports. More than half of the 6,824 ti­tles of im­ported medicines can be pro­duced in our coun­try, but this fig­ure cur­rently stands at only 27%. Med­i­ca­tions used in on­col­ogy, gy­ne­col­ogy, den­tistry, are com­pletely im­ported from abroad.

The state of af­fairs in sup­ply­ing state med­i­cal in­sti­tu­tions with medicines and med­i­cal prod­ucts re­mains un­sat­is­fac­tory. The pop­u­la­tion of our coun­try does not feel the re­sults of re­forms im­ple­mented in the coun­try at all. This is ev­i­denced by neg­a­tive re­views in the me­dia, the Pres­i­dent stressed.

There are no sys­tems for iden­ti­fy­ing drug needs and a data­base con­tain­ing spe­cific data on this. Noth­ing con­crete has been done about or­ga­niz­ing this year thou­sands of so­cial phar­ma­cies. 9 months have passed since the adop­tion of the de­cree es­tab­lish­ing seven free eco­nomic zones, but the cor­re­spond­ing work was not started in any zone. Their mas­ter plans have not been ap­proved; en­gi­neer­ing and com­mu­ni­ca­tion net­works have not been built.

In the phar­ma­ceu­ti­cal in­dus­try, the role of re­search in­sti­tutes is not felt. At the present time, on the ba­sis of their de­vel­op­ment, only 1.6 tons of medic­i­nal sub­stances are pro­duced with 16 names us­ing veg­etable raw ma­te­ri­als. In ad­di­tion, there are not enough per­son­nel in the in­dus­try who can ef­fec­tively work with mod­ern tech­nolo­gies.

An­a­lyz­ing these prob­lems, im­por­tant di­rec­tions for their elim­i­na­tion have been iden­ti­fied. In par­tic­u­lar, the task is to take ad­di­tional mea­sures to en­sure sta­bil­ity and pre­vent the ar­ti­fi­cial in­crease in drug prices in the do­mes­tic mar­ket. Re­spon­si­ble persons are given spe­cific in­struc­tions on the de­vel­op­ment and ap­proval of gen­eral plans for free eco­nomic zones, spe­cial­iz­ing in phar­ma­ceu­ti­cals, pro­vid­ing them with all nec­es­sary com­mu­ni­ca­tions.

The is­sues of train­ing spe­cial­ists in nar­row spe­cial­ties in phar­ma­ceu­ti­cals and or­ga­niz­ing in­tern­ships for in­dus­try work­ers at for­eign phar­ma­ceu­ti­cal en­ter­prises are also con­sid­ered.

Newspapers in English

Newspapers from Uzbekistan

© PressReader. All rights reserved.